ProCE Banner Activity

CE / CME

The Role of NPs and PAs in the Timely Diagnosis and Management of EoE: Diagnosing and Classifying EoE

Video

Experts discuss the role of pediatric and primary care NPs and PAs in recognizing and diagnosing patients of varying ages with eosinophilic esophagitis.

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurses/Nurse Practitioners: 0.25 NAPNAP contact hour

Released: December 13, 2023

Expiration: December 12, 2024

Share

Faculty

Megan O. Lewis

Megan O. Lewis, MSN, RN, CPNP-PC

Pediatric Nurse Practitioner
Division of Allergy & Immunology
Children’s Hospital of Philadelphia
Philadelphia, Pennsylvania

Amanda Michaud

Amanda Michaud, DMSc, PA-C, AE-C

Physician Assistant
Allergy/Clinical Immunology
Family Allergy Consultants
Jacksonville, Florida

Provided by

Provided by Partners for Advancing Clinical Education (PACE) in partnership with National Association of Pediatric Nurse Practitioners (NAPNAP)

ProCE Banner

Supporters

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Regeneron Pharmaceuticals, Inc

Sanofi

Partners

NAPNAP

ProCE Banner

Target Audience

The proposed educational program is intended for pediatric and primary care NPs and PAs who care for patients with eosinophilic esophagitis.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with EoE.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize signs and symptoms of EoE in pediatric and adult patients to facilitate early diagnosis

Disclosure

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

‌All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships. 

Primary Author

Megan O. Lewis, MSN, RN, CPNP-PC

Pediatric Nurse Practitioner
Division of Allergy & Immunology
Children’s Hospital of Philadelphia
Philadelphia, Pennsylvania

Megan O. Lewis, MSN, RN, CPNP-PC, has no relevant financial relationships to disclose.

Amanda Michaud, DMSc, PA-C, AE-C

Physician Assistant
Allergy/Clinical Immunology
Family Allergy Consultants
Jacksonville, Florida

Amanda Michaud, DMSc, PA-C, AE-C : consultant/advisor/speaker: Dermavant, Novartis, Pfizer, Regeneron.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 13, 2023, through December 12, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation


NAPNAP is an accredited provider of NAPNAP continuing education contact hours, approved by the National Association of Pediatric Nurse Practitioners Continuing Education Committee. This program is accredited for 0.25 NAPNAP CE contact hours of which 0 contain pharmacology content, per the National Association of Pediatric Nurse Practitioners Continuing Education Guidelines. Approval is valid until December 12, 2024. NPs should only claim credit commensurate with the extent of their participation.

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until December 12, 2024. PAs should only claim credit commensurate with the extent of their participation.